Dosing Down to a Science

OnDose is a simple blood test that helps oncologists to optimize infusional 5-FU therapy on an individual basis. OnDose provides the data for pharmacokinetically-guided dose adjustments of infusional 5-FU to help optimize dosing for patients with colorectal cancer.

In a phase 3, multicenter, randomized study (N=208), optimized dosing demonstrated proven benefits for both efficacy and toxicity.¹

• Provided significantly greater objective response rates (33.7% versus 17.3% with body surface area [BSA]-based dosing; P=.004)¹


• Despite having higher mean doses of 5-FU,* patients experienced significantly less toxicity (P=.003)¹
  • Patients experienced a 78% reduction in grades 3/4 diarrhea¹


• Optimized dosing demonstrated a trend toward increased median survival¹
  • 22 months versus 16 months with BSA-based dosing (P=.08)¹

With OnDose, dosing can be as individual as your patients

The OnDose Results Report is designed to provide you with an accurate and timely measurement of infusional 5-FU exposure in patients with colorectal cancer. The test results are used to help optimize an individualized dose for the next cycle and help guide your patients' doses into a clinically established target area under the curve range (20-24 mg•h/L).

Reference: 1. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099-2105.

Listen to the archived OnDose webcast

Recorded on June 18, 2009

Join Dr. Edward Chu for a webcast on pharmacokinetically-guided dosing of infusional 5-FU

Myriad Genetic Laboratories, Inc.
320 Wakara Way, Salt Lake City, UT 84108

1-800-469-7423 | E-mail: ondose@myriad.com
Myriad, the Myriad logo, OnDose, and the OnDose logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.